8 completed, 7 not yet recruiting, 7 unknown, 6 recruiting. 35 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 35 | Completed 8, Not yet recruiting 7, Unknown 7, Recruiting 6, Terminated 4, Withdrawn 2, Active not recruiting 1 |
Follow Hematologic Neoplasms: new trials by email Literature Review of Hematologic Neoplasms trials Research Report on Hematologic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies iMagic Injection (IMV101), iMagic Injection (IMV102) - Relapsed/Refractory Hematologic Malignancies | Early Phase 1 | Not yet recruiting | Suzhou Immunofoco Biotechnology Co., Ltd | 30 | 2026-12-10 | 2026-11-04 |
| Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation Venetoclax, Hematopoietic Cell Transplantation Conditioning Regimen, Kidney Transplant - Kidney Failure Chronic, Stem Cell Transplant | Early Phase 1 | Recruiting | Massachusetts General Hospital | 3 | 2026-02-04 | 2026-10-14 |
| Exploratory Study on the Treatment of Recurrent and Refractory Hematological Malignancies With WGb-0302 Injection WGb-0302 injection - Hematological Malignancies | Early Phase 1 | Not yet recruiting | Sichuan University | 20 | 2026-02-01 | 2026-01-23 |
| Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies In vivo CAR-T drug targeting CD20 based on mRNA-LNP - Hematological Malignancies | Early Phase 1 | Not yet recruiting | The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army | 47 | 2026-01-26 | 2026-01-23 |
| HMCT/CT2401: Abatacept GVHD Prophylaxis Following Omidubicel HCT Abatacept - Hematologic Malignancy | Early Phase 1 | Recruiting | Duke University | 10 | 2025-11-12 | 2026-11-06 |
| A Clinical Study to Evaluate the Safety and Efficacy of Anti-human CD 7 CAR-NK Cell Injection in Subjects With Relapsed and Refractory CD7-positive Hematological Malignancy Anti-human CD7 CAR-NK cell injection - Immunology, Hematologic Malignancies | Early Phase 1 | Not yet recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 18 | 2025-09-01 | 2025-08-12 |
| A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in Adult Participants With Relapsed/Refractory CD19-positive B-cell Malignant Hematological Tumors GT719 Injection - Hematological Malignancy (Leukemia- Lymphoma) | Early Phase 1 | Recruiting | Grit Biotechnology | 34 | 2025-03-10 | 2025-12-30 |
| Early Clinical Study of JY306 Universal NK Cell Injection in the Treatment of Adult Relapsed or Refractory CD70+ Malignant Hematologic Tumors JY306 universal NK cell injection - Relapsed or Refractory Hematological Malignancies | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 18 | 2025-02-15 | 2025-02-20 |
| CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial Autologous CAR123 T lymphocytes - Leukemia, Myeloid, Acute(AML), Precursor Cell Lymphoblastic Leukemia-Lymphoma | Early Phase 1 | Active not recruiting | Institute of Hematology and Blood Transfusion, Czech Republic | 18 | 2024-10-23 | 2026-09-14 |
| Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score - Hematologic Malignancy, Bone Marrow Transplant Rejection | Early Phase 1 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 8 | 2024-09-19 | 2026-10-05 |
| Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion Alteplase, Placebo Administration - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 30 | 2023-08-17 | 2026-08-17 |
| RD13-02 for Patients With r/r CD7+ T Cell Hematologic Malignancies RD13-02 cell infusion - Hematologic Malignancies | Early Phase 1 | Completed | Henan Cancer Hospital | 6 | 2023-06-26 | 2024-11-22 |
| RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL RD13-02 cell infusion - Neoplasms, Hematologic Neoplasms | Early Phase 1 | Completed | Xiaoyu Zhu | 4 | 2023-04-30 | 2024-11-21 |
| Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies RD13-02 cell infusion - Neoplasms, Hematologic Neoplasms | Early Phase 1 | Completed | MEI HENG | 2 | 2023-03-10 | 2026-02-03 |
| Research Development(RD)13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7(CD7)+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML) RD13-02 cell infusion - Neoplasms, Hematologic Neoplasms | Early Phase 1 | Completed | Kai Lin Xu,MD | 8 | 2023-03-08 | 2024-11-21 |
| CD7 CAR-T for Patients With r/r CD7+ T-ALL/T-LBL RD13-02 cell infusion - Neoplasms, Hematologic Neoplasms | Early Phase 1 | Completed | He Huang | 20 | 2023-02-09 | 2024-11-21 |
| Safety, Tolerability and Preliminary Efficacy of Engineered Red Blood Cell in Patients With Advanced Malignancies engineered red blood cell - Cancer, Solid Tumor | Early Phase 1 | Unknown | Westlake Therapeutics | 30 | 2023-01-16 | 2024-07-24 |
| A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001) isatuximab 10 mg/kg - Platelet Refractoriness, Hematologic Malignancy | Early Phase 1 | Terminated | Firas El Chaer, MD | 3 | 2022-11-29 | 2024-07-31 |
| Thermal Therapy for the Treatment of Depression in Cancer Survivors, the S-WARM Study Quality-of-Life Assessment, Questionnaire Administration, Thermotherapy - Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2021-05-06 | 2022-05-12 | |
| Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies CT125A cells, Cyclophosphamide, fludarabine - CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL) | Early Phase 1 | Unknown | Huazhong University of Science and Technology | 18 | 2021-03-01 | 2021-02-23 |
Showing 20 of 35. Sign in to see all of them.
Myelodysplastic Syndromes (6) · Neoplasms (6) · Leukemia, Myeloid, Acute (5) · Hematologic Diseases (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Leukemia (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Mantle-Cell (3) · Lymphoma, Non-Hodgkin (3) · Multiple Myeloma (3) · Myeloproliferative Disorders (3) · Polycythemia Vera (3)
Hemic and Lymphatic Diseases (35) · Neoplasms by Site (33) · Hematologic Diseases (31) · Neoplasms (29) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Disease Attributes (9) · Bone Marrow Diseases (8) · Neoplasms by Histologic Type (8) · Chronic Disease (6) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Lymphatic Diseases (6) · Leukemia, Lymphoid (5) · Leukemia, Myeloid (5)
Abatacept (1) · Biopsy (1) · CF regimen (1) · Cell- and Tissue-Based Therapy (1) · Continuous Positive Airway Pressure (1) · Counseling (1) · Diathermy (1) · Hydrocodone (1) · Hydromorphone (1) · Hyperthermia, Induced (1) · Kidney Transplantation (1) · Levorphanol (1) · Lisaftoclax (1) · Morphine (1) · Observation (1)
M.D. Anderson Cancer Center (4) · Northwestern University (2) · Zhejiang University (2) · iCell Gene Therapeutics (2) · Ascentage Pharma Group Inc. (1) · Duke University (1) · Firas El Chaer, MD (1) · Grit Biotechnology (1) · He Huang (1) · Henan Cancer Hospital (1) · Huazhong University of Science and Technology (1) · Institute of Hematology and Blood Transfusion, Czech Republic (1) · Kai Lin Xu,MD (1) · MEI HENG (1) · Massachusetts General Hospital (1)
China (15) · United States (14) · Australia (1) · Czechia (1)
Fang Liu, MD, PhD (2) · Hongyu Zhang, MD, PhD (2) · Akhila S Reddy (1) · Anurag K Singh (1) · Brady Stein, MD (1) · Christian B Gocke, MD, PhD (1) · David Marin, MD (1) · Firas El Chaer, MD (1) · Gerardo Colon-Otero, M.D. (1) · Horiana Grosu, M D (1) · Jan Vydra, MD, PhD (1) · Jeffrey J. Raizer, MD (1) · Jianfeng Zhou, PhD, MD (1) · Krishna Sundar (1) · Partow Kebriaei, MD (1)
P01CA148600 (1), P30CA015083 (1), P30CA042014 (1), P30CA060553 (1), P30CA072720 (1)